Zobrazeno 1 - 10
of 1 393
pro vyhledávání: '"D Maraninchi"'
Autor:
Anne Mathieu-Boué, Pierre Demolis, Jean-François Bergmann, M. Aoustin, C. Atlani, F. Bassompierre, R. Benamouzig, M.-J. Bonavita, L. Borella, F. Calvo, C. Caulin, D. Cellier, M. Dahan, V. Daura, F. De Beels, N. De Vernejoul, V. Diebolt, N. Dumarcet, I. Durand Zaleski, E. Fery Lemonnier, J. Genève, I. Giri, D. Golinelli, C. Labreveux, J.-F. Latour, D. Maraninchi, V. Meresse, L. Mignot, D. Morlet, S. Pépin, P. Ravaud, C. Riché, A. Rouleau, P. Tilleul, P. Viens
Publikováno v:
Therapie. 61(4)
Drugs used in oncology represent more than half of the innovative and costly drugs which are not covered by a Group Homogene de Soins (DRG type classification) within the context of the case-mix based payment system (termed T2A). For these drugs, goo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca266e08379d0a664fbfb3face31cfd8
https://pubmed.ncbi.nlm.nih.gov/27393309
https://pubmed.ncbi.nlm.nih.gov/27393309
Autor:
Antelo-Cea, Damián A.1,2 (AUTHOR) damian.antelo.cea@gmail.com, Martínez-Rojas, Laura1 (AUTHOR) lala.mrojas@gmail.com, Cabrerizo-Ibáñez, Izan1 (AUTHOR) izancabrerizo7ub@gmail.com, Roudi Rashtabady, Ayda1,2 (AUTHOR) roudi.r@gmail.com, Hernández-Alvarez, María Isabel1,2,3 (AUTHOR) mihernandez@ub.edu
Publikováno v:
International Journal of Molecular Sciences. Oct2024, Vol. 25 Issue 20, p11237. 21p.
Autor:
Chris Twelves, D Maraninchi, Joseph McKendrick, Robert C. F. Leonard, AS Bexon, N Barak-Wigler, CA Chan-Navarro, S Vukelja, Joyce A. O'Shaughnessy, V Gorbounova, WG Harker
Publikováno v:
Annals of Oncology. 17:1379-1385
Background: In a phase III trial, 3-weekly capecitabine (1250 mg/m 2 twice daily days 1–14) plus docetaxel (75 mg/m 2 day 1) demonstrated significantly superior overall survival to 3-weekly docetaxel (100 mg/m 2 day 1). We report a retrospective an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b1df4d79bca625dcd755568b607759
https://doi.org/10.1093/annonc/mdl134
https://doi.org/10.1093/annonc/mdl134
Autor:
Anne Mathieu-Boué, Pierre Demolis, Jean-François Bergmann, M. Aoustin, C. Atlani, F. Bassompierre, R. Benamouzig, M.-J. Bonavita, L. Borella, F. Calvo, C. Caulin, D. Cellier, M. Dahan, V. Daura, F. De Beels, N. De Vernejoul, V. Diebolt, N. Dumarcet, I. Durand Zaleski, E. Fery Lemonnier, J. Genève, I. Giri, D. Golinelli, C. Labreveux, J.-F. Latour, D. Maraninchi, V. Meresse, L. Mignot, D. Morlet, S. Pépin, P. Ravaud, C. Riché, A. Rouleau, P. Tilleul, P. Viens
Publikováno v:
Therapies. 61:305-308
Les medicaments utilises en cancerologie representent plus de la moitie des medicaments innovants et couteux pris en charge hors d'un groupe homogene de soins dans le cadre de la tarification a l'activite. Pour ces medicaments, des referentiels de bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4014c868cef1c44a0788ee6dcdcd914
https://doi.org/10.2515/therapie:2006054
https://doi.org/10.2515/therapie:2006054
Publikováno v:
La Revue de Médecine Interne. 26:470-478
Resume Propos. – Les cancers du sein representent une entite pathologique complexe et heterogene, resultant de multiples alterations moleculaires dont l'identification croissante, ces dernieres annees, permet d'envisager des retombees majeures sur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fa99c575a5dcb27de74683d1b76d4a7
https://doi.org/10.1016/j.revmed.2004.11.012
https://doi.org/10.1016/j.revmed.2004.11.012
Autor:
R. Bouabdallah, Patrick Ladaique, Didier Blaise, Karin Bilger, Mohamad Mohty, Norbert Vey, Christian Chabannon, D. Sainty, J. Camerlo, C. Arnoulet, Vadim Ivanov, D. Maraninchi, Catherine Faucher, V.J. Bardou
Publikováno v:
Transfusion. 44:501-508
BACKGROUND: RBCT (RBCT) requirements of stem cell transplant (SCT) recipients are often substantial and may be related to transplant type. STUDY DESIGN AND METHODS: An analysis was done of RBCT requirements and Hb recovery kinetic in the first 60 day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d50b54cc36969d0994b70d9f59a4a5a
https://doi.org/10.1111/j.1537-2995.2004.03317.x
https://doi.org/10.1111/j.1537-2995.2004.03317.x
Autor:
Patrice Viens, C. Chabannon, François Bertucci, Jocelyne Jacquemier, D. Thouvenin, D. Maraninchi
Publikováno v:
Oncologie. 6:93-98
L’heterogeneite des tumeurs est un concept aujourd’hui bien etabli en oncologie medicale. La reconnaissance de cette heterogeneite implique une prise en charge multidisciplinaire de la maladie, et une caracterisation aussi precise que possible de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec0570f4a89258843b8a6053093bfcbc
https://doi.org/10.1007/s10269-004-0023-x
https://doi.org/10.1007/s10269-004-0023-x
Autor:
F. Viret, Anthony Gonçalves, D. Maraninchi, J. Camerlo, G. Gravis, C. Tarpin, M. Vitot, Jean-Marc Schiano, Patrick Ladaique, A C Braud, A. Madroszyk, D. Coso, Patrice Viens, François Bertucci, G. Damaj
Publikováno v:
Oncologie. 6:49-53
La fatigue et l’anemie sont les symptomes les plus frequemment rapportes par les patients en cours de chimiotherapie. Les traitements curatifs sont souvent d’une efficacite retardee et insuffisante, et ont un cout non negligeable. Notre strategie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9dfa73593560dce7ce737ffca4f6786
https://doi.org/10.1007/s10269-004-0015-x
https://doi.org/10.1007/s10269-004-0015-x
Autor:
C Chabannon, Dominique Genre, A. Goncalvez, D Maraninchi, J. Camerlo, G Gravis, Patrice Viens, Christel Protière, V Moutardier, V-J Bardou, G Houvenaeghel, François Bertucci, A C Braud
Publikováno v:
Bone Marrow Transplantation
Bone Marrow Transplantation, Nature Publishing Group, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩
Bone Marrow Transplantation, Nature Publishing Group, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩
International audience; The aim of this study was to evaluate and to compare in terms of toxicity the modulations of dose intensity of cyclophosphamide and doxorubicin in adjuvant chemotherapy for high-risk breast cancer. Four cycles of sequential hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c968c20f8884c91a77b32a62055c89c
https://doi.org/10.1038/sj.bmt.1703556
https://doi.org/10.1038/sj.bmt.1703556
Autor:
P, Viens, C, Chabannon, P, Pouillard, M, Janvier, W, Brugger, J Y, Blay, F, Oberling, R, Capdeville, C, Newman, V, Méresse, Z X, Xu, E, Platzer, P, Van der Auwera, D, Maraninchi
Publikováno v:
Journal of Clinical Oncology. 20:24-36
PURPOSE: To evaluate the safety, pharmacokinetics, and efficacy of three different dose levels of pegylated granulocyte colony-stimulating factor (Ro 25-8315) on progenitor cell mobilization and hematologic recovery in cancer patients. PATIENTS AND M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6818342a1a8a0a441e743589214a2533
https://doi.org/10.1200/jco.2002.20.1.24
https://doi.org/10.1200/jco.2002.20.1.24